Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1212-1218

  Wang, Cong ^a,b   Lin, Shaoqiang ^c   Nie, Yanfang ^d   Jia, Xinglong ^a   Wang, Jing ^c   Xiao, Jian ^c   Wu, Jianzhang ^c   Li, Xiaokun ^a   Wu, Xiaoping ^a,c  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BINDING PEPTIDE BINDING PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 3; P7 BINDING PEPTIDE; STATHMIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN CACO 2; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; TWO DIMENSIONAL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL CYCLE; COLONIC NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; HT29 CELLS; HUMANS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77953187652     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01501.x     Document Type: Article

References (24)

1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009, 8:235-53.
2. Dailey L, Ambrosetti D, Mansukhani A. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005, 16:233-47.
3. Cronauer MV, Schulz WA, Seifert HH. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003, 43:309-19.
4. Presta M, Dell'Era P, Mitola S. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-78.
5. Wu X, Yan Q, Huang Y. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med 2008, 10.1111/j.1582-4934.2008.00506.x, doi
6. Jemal A, Siegel R, Ward E. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
7. Galzie Z, Fernig DG, Smith JA. Invasion of human colorectal carcinoma cells is promoted by endogenous basic fibroblast growth factor. Int J Cancer 1997, 71:390-5.
8. Stoeltzing Q, Liu W, Reinmuth N. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 2003, 10:722-33.
9. Tassi E, Wellstein A. The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. Semin Oncol 2006, 33:S50-6.
10. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 7:248-54.
11. Neuhoff V, Arold N, Taube D. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988, 9:255-62.
12. Lessor TJ, Yoo JY, Xia X. Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol 2008, 3:321-9.
13. Zhang Y, Akinmade D, Hamburger AW. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Cancer Lett 2008, 265:298-306.
14. Ek P, Pettersson G, Ek B. Identification and characterization of a mammalian 14-kDa phosphohistidine phosphatase. Eur J Biochem 2002, 269:5016-23.
15. Klumpp S, Hermesmeier J, Selke D. Protein histidine phosphatase: a novel enzyme with potency for neuronal signaling. J Cereb Blood Flow Metab 2002, 22:1420-4.
16. Klumpp S, Bechmann G, Mäurer A. ATP-citrate lyase as a substrate of protein histidine phosphatase in vertebrates. Biochem Biophys Res Commun 2003, 306:110-5.
17. Mäurer A, Wieland T, Meissl F. The beta-subunit of G proteins is a substrate of protein histidine phosphatase. Biochem Biophys Res Commun 2005, 334:1115-20.
18. Rana S, Maples PB, Senzer N. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008, 8:1461-70.
19. Roos G, Brattsand G, Landberg G. Expression of oncoprotein 18 in human leukemias and lymphomas. Leukemia 1993, 7:1538-46.
20. Price DK, Ball JR, Bahrani-Mostafavi Z. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 2000, 18:722-30.
21. Bièche I, Lachkar S, Becette V. Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 1998, 78:701-9.
22. Luo XN, Mookerjee B, Ferrari A. Regulation of phospho-protein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 1994, 269:10312-8.
23. Jeha S, Luo XN, Beran M. Antisense RNA inhibition of phospho-protein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 1996, 56:1445-50.
24. Pardo OE, Arcaro A, Salerno G. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 2002, 277:12040-6.